1. Home
  2. WNC vs ALT Comparison

WNC vs ALT Comparison

Compare WNC & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

WNC

Wabash National Corporation

HOLD

Current Price

$9.84

Market Cap

397.9M

Sector

Industrials

ML Signal

HOLD

Logo Altimmune Inc.

ALT

Altimmune Inc.

HOLD

Current Price

$5.12

Market Cap

415.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WNC
ALT
Founded
1985
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Construction/Ag Equipment/Trucks
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
397.9M
415.3M
IPO Year
1991
N/A

Fundamental Metrics

Financial Performance
Metric
WNC
ALT
Price
$9.84
$5.12
Analyst Decision
Hold
Strong Buy
Analyst Count
1
6
Target Price
$9.00
$16.00
AVG Volume (30 Days)
487.5K
6.4M
Earning Date
02-04-2026
02-26-2026
Dividend Yield
3.26%
N/A
EPS Growth
N/A
N/A
EPS
6.15
N/A
Revenue
$1,638,115,000.00
$20,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$14.16
N/A
P/E Ratio
$1.60
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.78
$2.90
52 Week High
$16.91
$7.73

Technical Indicators

Market Signals
Indicator
WNC
ALT
Relative Strength Index (RSI) 50.56 56.64
Support Level $9.74 $5.19
Resistance Level $10.16 $6.36
Average True Range (ATR) 0.42 0.48
MACD -0.09 0.14
Stochastic Oscillator 14.19 46.98

Price Performance

Historical Comparison
WNC
ALT

About WNC Wabash National Corporation

Wabash National Corp operates as the innovation leader of connected solutions for the transportation, logistics, and distribution industries. The Company manages its business in two operating and reportable segments: Transportation Solutions and Parts & Services. It designs and manufactures products including dry freight and refrigerated trailers, platform trailers, tank trailers, dry and refrigerated truck bodies, structural composite panels and products, trailer aerodynamic solutions, and specialty food-grade processing equipment.

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: